The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy

被引:6
作者
Chan, Carmen W. H. [1 ]
Tsui, Stephen K. W. [2 ]
Law, Bernard M. H. [1 ]
So, Winnie K. W. [1 ]
Tang, Fiona W. K. [1 ]
Wong, Cho-Lee [1 ]
机构
[1] Chinese Univ Hong Kong, Nethersole Sch Nursing, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China
来源
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2016年 / 17卷 / 03期
关键词
immune system; immunotherapy; chemotherapy; lung cancer; OPEN-LABEL; PHASE-II; TRIAL; IPILIMUMAB; MULTICENTER; COMBINATION; VACCINATION; RESISTANCE; DOCETAXEL; NIVOLUMAB;
D O I
10.3390/ijms17030286
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lung cancer is ranked first worldwide as one of the main cancers in terms of prevalence and mortality rate. The development of effective treatment strategies against lung cancer is therefore of paramount importance. Traditionally, chemotherapy was employed in the treatment of various cancers. However, the non-specific nature of the actions of chemotherapeutic drugs and the potential for tumors to develop resistance to these drugs may render chemotherapy a less favorable option for cancer treatment. Immunotherapy provides an alternative strategy for this purpose. It involves the utilization of the immune system and the immune effector cells to elicit an immune response to the tumors, thereby eliminating them. Strategies include the administration of pro-inflammatory cytokines for immune stimulation, the removal of immunological checkpoints using monoclonal antibodies, and the use of cancer vaccines to enhance immunity against tumors. This article summarizes the above strategies, highlights the reasons why immunotherapy is superior to chemotherapy for the purpose of tumor removal, and reviews the recent clinical studies comparing the clinical outcomes of patients undergoing immunotherapy and chemotherapy. The article also describes advances in immunotherapeutic strategies for the treatment of lung cancer.
引用
收藏
页数:12
相关论文
共 28 条
  • [1] [Anonymous], GLOB 2012 EST CANC I
  • [2] Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
    Bersanelli, Melissa
    Buti, Sebastiano
    Camisa, Roberta
    Brighenti, Matteo
    Lazzarelli, Silvia
    Mazza, Giancarlo
    Passalacqua, Rodolfo
    [J]. CANCERS, 2014, 6 (04) : 2035 - 2048
  • [3] The Hedgehog Receptor Patched Functions in Multidrug Transport and Chemotherapy Resistance
    Bidet, Michel
    Tomico, Amandine
    Martin, Patrick
    Guizouarn, Helene
    Mollat, Patrick
    Mus-Veteau, Isabelle
    [J]. MOLECULAR CANCER RESEARCH, 2012, 10 (11) : 1496 - 1508
  • [4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [6] Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
    Brunsvig, Paal Fr.
    Kyte, Jon Amund
    Kersten, Christian
    Sundstrum, Stein
    Muller, Mona
    Nyakas, Marta
    Hansen, Gaute L.
    Gaudernack, Gustav
    Aamdal, Steinar
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (21) : 6847 - 6857
  • [7] Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
    Butts, Charles
    Maksymiuk, Andrew
    Goss, Glenwood
    Soulieres, Denis
    Marshall, Ernie
    Cormier, Yvon
    Ellis, Peter M.
    Price, Allan
    Sawhney, Ravinder
    Beier, Frank
    Falk, Martin
    Murray, Nevin
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (09) : 1337 - 1342
  • [8] Timeline - Chemotherapy and the war on cancer
    Chabner, BA
    Roberts, TG
    [J]. NATURE REVIEWS CANCER, 2005, 5 (01) : 65 - 72
  • [9] Eichbaum C, 2011, ANTICANCER RES, V31, P3219
  • [10] Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
    Horvat, Troy Z.
    Adel, Nelly G.
    Thu-Oanh Dung
    Momtaz, Parisa
    Postow, Michael A.
    Callahan, Margaret K.
    Carvajal, Richard D.
    Dickson, Mark A.
    D'Angelo, Sandra P.
    Woo, Kaitlin M.
    Panageas, Katherine S.
    Wolchok, Jedd D.
    Chapman, Paul B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) : 3193 - +